Breast cancer recurrent
Information
- Disease name
- Breast cancer recurrent
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02915445 | Active, not recruiting | Phase 1 | EpCAM CAR-T for Treatment of Advanced Solid Tumors | July 2016 | July 2025 |
| NCT02248571 | Completed | Phase 4 | Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab | August 2014 | September 30, 2017 |
| NCT02844335 | Completed | Phase 1/Phase 2 | Combination of Cryosurgery and NK Immunotherapy for Advanced Breast Cancer | July 1, 2016 | July 1, 2019 |
| NCT01552655 | Completed | N/A | Breast Cancer Recurrence - the Accuracy of Dual-time PET/CT | December 2011 | December 2014 |
| NCT04330339 | Completed | N/A | Prolonged Nightly Fasting in Breast Cancer Survivors | July 24, 2020 | July 5, 2022 |
| NCT05301010 | Completed | Phase 3 | Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients | February 2, 2018 | February 19, 2021 |
| NCT05301530 | Completed | Phase 1 | Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients. | May 27, 2019 | February 19, 2021 |
| NCT05406661 | Not yet recruiting | Registry of Local Recurrences After Breast-conserving Surgery | December 1, 2023 | December 2026 | |
| NCT06458413 | Recruiting | Phase 2 | Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer | June 5, 2024 | December 5, 2025 |
| NCT05730608 | Recruiting | N/A | 18F-FDG PET/CT Imaging for Breast Cancer | February 16, 2023 | December 31, 2032 |
| NCT05464082 | Recruiting | Phase 2 | Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC | January 6, 2023 | September 30, 2027 |
| NCT05592938 | Recruiting | N/A | Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE) | June 27, 2023 | June 27, 2027 |
| NCT03820830 | Recruiting | Phase 3 | Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer | August 27, 2019 | November 1, 2026 |
| NCT02947061 | Unknown status | Phase 2 | S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer | April 2015 | April 2019 |